Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 13/20 | 0.46 |
| ▸ | PPARG | P37231 | 12/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.40 |
| ▸ | FABP3 | P05413 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562599 | 0.79 | PTGDR2 (0.48) | PPARG | |
| SCHEMBL10203746 | 0.76 | ALDH1A1 (0.41) | — | |
| SCHEMBL10203752 | 0.75 | PPARA (0.43) | SMN1; SMN2PPARAPPARG | |
| SCHEMBL11359371 | 0.75 | SMN1; SMN2 (0.73) | SMN1; SMN2PPARAPPARG | |
| SCHEMBL10203729 | 0.73 | FFAR1 (0.35) | SMN1; SMN2PDCD1CD274 | |
| SCHEMBL562872 | 0.72 | ALDH1A1 (0.41) | — | |
| SCHEMBL2911933 | 0.72 | KAT6A (0.37) | SMN1; SMN2CD274 | |
| SCHEMBL10203744 | 0.72 | FFAR1 (0.42) | SMN1; SMN2 | |
| SCHEMBL10264059 | 0.72 | RECQL (0.46) | SMN1; SMN2 | |
| SCHEMBL562863 | 0.72 | LMNA (0.41) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423176-A1 | CARBOXYLIC ACID COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | GPR119, GPR65, GPR55 | SMN1; SMN2 3487/4885PPARA 104/4885PPARG 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.